USPTO serial 87823394
POLYBIOTIC
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BHUPATHI, TARA
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with POLYBIOTIC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christina M. Licursi
CHRISTINA M. LICURSI WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210-2206UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Therapeutic pharmaceuticals for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; pharmaceutical preparations for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; therapeutic pharmaceuticals for modulating metabolism; pharmaceutical preparations and agents to modulate metabolism; pharmaceutical agents that modulate metabolism for scientific and research use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 21, 2019 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 21, 2019 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 19, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 22, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 22, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 2, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 17, 2018 | ALIE | ASSIGNED TO LIE | — |
| Nov 27, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 27, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 27, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 27, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 27, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 6, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 5, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 5, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 3, 2018 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 3, 2018 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 3, 2018 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 27, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 13, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |